Aethlon Medical, Inc. (NASDAQ:AEMD) Sees Significant Growth in Short Interest

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 330,345 shares, a growth of 1,045.3% from the May 14th total of 28,844 shares. Currently, 21.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 3,203,228 shares, the days-to-cover ratio is presently 0.1 days.

Aethlon Medical Stock Performance

NASDAQ:AEMD traded down $0.13 during mid-day trading on Thursday, hitting $1.89. 147,471 shares of the company’s stock traded hands, compared to its average volume of 346,391. The company has a market cap of $2.97 million, a PE ratio of -0.13 and a beta of 1.49. The firm’s 50 day simple moving average is $2.22 and its 200 day simple moving average is $2.50. Aethlon Medical has a 1 year low of $1.36 and a 1 year high of $27.40.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a report on Monday, April 20th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new stake in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical as of its most recent SEC filing. Hedge funds and other institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.